|
Category
|
COVID-19 (N = 129)
|
H1N1 (N = 7)
|
Total (N = 136)
|
|---|
|
Registration
|
|
ChiCTR
|
122 (94.6%)
|
5 (71.4%)
|
127 (93.4%)
|
|
ClinicalTrials.gov
|
7 (5.4%)
|
2 (28.6%)
|
9 (6.6%)
|
|
Study type
|
|
Interventional study
|
107 (82.9%)
|
5 (71.4%)
|
112 (82.4%)
|
|
Observational study
|
22 (17.1%)
|
2 (28.6%)
|
24 (17.6%)
|
|
Primary sponsor
|
|
Hospital
|
107 (82.9%)
|
5 (71.4%)
|
112 (82.4%)
|
|
University
|
12 (9.3%)
|
N/A
|
12 (8.8%)
|
|
Others
|
10 (7.8%)
|
2 (28.6%)
|
12 (8.8%)
|
|
Intervention
|
|
Chinese herbal products
|
42 (32.6%)
|
4 (57.1%)
|
46 (33.8%)
|
|
TCM treatment
|
16 (12.4%)
|
3 (42.9%)
|
19 (14.0%)
|
|
Chinese herbal formula
|
40 (31.0%)
|
N/A
|
40 (29.4%)
|
|
Integration of traditional Chinese and Western medicine
|
11 (8.5%)
|
N/A
|
11 (8.1%)
|
|
Nonpharmaceutical treatment of TCM
|
8 (6.2%)
|
N/A
|
8 (5.9%)
|
|
Others
|
12 (9.3%)
|
N/A
|
12 (8.8%)
|
|
Assignment
|
|
Parallel
|
81 (62.8%)
|
5 (71.4%)
|
86 (63.2%)
|
|
Sequential
|
15 (11.6%)
|
N/A
|
15 (11.0%)
|
|
Single arm
|
7 (5.4%)
|
N/A
|
7 (5.1%)
|
|
Factorial
|
2 (1.6%)
|
N/A
|
2 (1.5%)
|
|
Others
|
5 (3.9%)
|
2 (28.6%)
|
7 (5.1%)
|
|
Not reported
|
19 (14.7%)
|
N/A
|
19 (14.0%)
|
|
Method of allocation
|
|
Randomized
|
83 (64.3%)
|
5 (71.4%)
|
88 (64.7%)
|
|
Non-randomized
|
45 (34.9%)
|
2 (28.6%)
|
47 (34.6%)
|
|
Quasi-randomized
|
1 (0.8%)
|
N/A
|
1 (0.7%)
|
|
Masking
|
|
Quadruple blind
|
1 (0.7%)
|
N/A
|
1 (0.7%)
|
|
Triple blind
|
1 (0.7%)
|
N/A
|
1 (0.7%)
|
|
Double blind
|
8 (6.2%)
|
1 (14.3%)
|
9 (6.6%)
|
|
Open label
|
36 (27.9%)
|
1 (14.3%)
|
37 (27.2%)
|
|
Not reported
|
83 (64.3%)
|
5 (71.4%)
|
88 (64.7%)
|
|
Recruitment status
|
|
Pending
|
58 (45.0%)
|
N/A
|
58 (42.6%)
|
|
Recruiting
|
68 (52.7%)
|
3 (42.9%)
|
71 (52.2%)
|
|
Suspended
|
2 (1.6%)
|
N/A
|
2 (1.5%)
|
|
Completed
|
1 (0.8%)
|
4 (57.1%)
|
5 (3.7%)
|
|
Prospective and retrospective registration
|
|
Retrospective
|
19 (14.7%)
|
N/A
|
19 (14.0%)
|
|
Prospective
|
110 (85.3%)
|
7 (100.0%)
|
117 (86.0%)
|
|
IPD sharing plan
|
|
Yes
|
119 (92.2%)
|
6 (85.7%)
|
125 (91.9%)
|
|
No
|
3 (2.3%)
|
N/A
|
3 (2.2%)
|
|
N/A
|
7 (5.4%)
|
1 (14.3%)
|
8 (5.9%)
|
- ChiCTR Chinese Clinical Trial Registry, TCM traditional Chinese medicine, COVID-19 severe acute respiratory syndrome coronavirus 2, H1N1 H1N1 influenza, N/A not available
